Becton Dickinson
BDX
$144.43
-0.62%
Becton, Dickinson and Company (BD) is a global medical technology firm operating in the Healthcare sector, specifically within Medical Instruments & Supplies. It is the world's largest manufacturer and distributor of medical surgical products like needles and syringes, and also produces diagnostic instruments, reagents, and flow cytometry systems. The company is a market leader with a diversified portfolio across four segments: BD Medical Essentials, Interventional, Connected Care, and Biopharma. The current investor narrative is focused on the company's post-spinoff operational execution, as evidenced by a recent strong quarterly earnings beat and a raised full-year profit outlook, which signals management confidence in underlying business strength despite broader market skepticism and recent stock price weakness.…
BDX
Becton Dickinson
$144.43
Related headlines
BDX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $187.76 and implied upside of +30.0% versus the current price.
Average Target
$187.76
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$116 - $188
Analyst target range
Analyst coverage appears limited, with data indicating only 4 analysts providing estimates, which is low for a company of BDX's size and suggests potentially less efficient price discovery. The consensus sentiment, inferred from recent institutional actions, is mixed but leans cautiously optimistic; among recent ratings, there are 4 Buy actions, 3 Neutral/Equal Weight actions, and 1 Sector Perform. The average target price is not explicitly provided in the data, but the estimated EPS average for the forward period is $16.51, which, when combined with the forward PE of 10.97x, implies a potential price target in the low $180s, representing significant upside from the current $147.12 if achieved. The target range, implied by estimated EPS lows of $16.34 and highs of $16.80, is relatively tight, indicating stronger conviction in the near-term earnings trajectory despite the stock's weak performance. The recent news of a raised profit outlook and a new CFO appointment could be catalysts that narrow the gap between the current price and analyst expectations, but the limited number of covering analysts means investor sentiment can be disproportionately influenced by a few key reports.
Bulls vs Bears: BDX Investment Factors
The evidence currently tilts bearish due to the stock's severe price deterioration, anemic revenue growth, and persistent relative weakness. However, the bull case is anchored in a compelling valuation disconnect, with a forward P/E of 10.97x pricing in a dramatic earnings recovery that, if achieved, offers significant upside. The most important tension in the investment debate is whether the company's raised profit outlook and strong cash generation can overcome the market's skepticism about its growth trajectory post-spinoff. The resolution of this tension—specifically, whether upcoming quarters demonstrate sustained earnings momentum—will determine if the stock is a deep value opportunity or a value trap.
Bullish
- Strong Forward Earnings Outlook: The forward P/E of 10.97x is exceptionally low for a healthcare leader and represents a significant discount to the trailing P/E of 25.13x. This implies the market expects a sharp earnings recovery, with consensus EPS estimates averaging $16.51 for the forward period, which would support a price in the low $180s.
- Robust Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $2.631 billion. This funds a healthy dividend (payout ratio of 71.3%) and provides operational flexibility, supporting a conservative balance sheet with a debt-to-equity ratio of 0.76.
- Management Confidence Post-Spinoff: Recent news highlights a strong Q2 earnings beat and a raised full-year profit outlook. This operational strength, coupled with a new CFO appointment, signals management confidence in the underlying business despite the stock's weak performance.
- Deep Value Relative to Recent History: The stock is down 24.5% YTD and trades near the bottom of its 52-week range, at 78.5% of the distance from its high of $187.35 to its low of $127.59. Its current trailing P/E of 25.13x is well below recent highs of 33.5x-38.9x, suggesting the market has priced out previous optimism.
Bearish
- Severe Technical Downtrend & Weakness: The stock is in a pronounced downtrend, down 24.5% YTD and 15.4% over the past year. It has shown severe relative weakness, underperforming the SPY by 26.9% over the past 3 months and 43.6% over the past year, indicating persistent institutional selling.
- Anemic Revenue Growth Trajectory: Recent quarterly revenue growth was a modest 1.63% YoY, and revenue declined sequentially from $5.89B to $5.25B. This lack of top-line momentum, coupled with volatile gross margins (ranging from 42.8% to 47.5%), raises concerns about post-spinoff growth acceleration.
- Limited Analyst Coverage & Sentiment: Only 4 analysts are providing estimates, which is low for a company of this size and suggests less efficient price discovery. While recent ratings show a mix (4 Buy, 3 Neutral, 1 Sector Perform), the limited coverage means sentiment can swing sharply on single reports.
- Compressed Profitability Metrics: Profitability has softened, with a quarterly net margin of 7.68% and operating margin of 11.30%. Return metrics are modest, with ROE at 6.61% and ROA at 4.38%, reflecting the capital-intensive nature of the business and limited earnings power at current scale.
BDX Technical Analysis
The stock is in a pronounced downtrend, having declined 15.36% over the past year and 24.53% year-to-date as of the current price of $147.12. It is trading near the bottom of its 52-week range, at approximately 78.5% of the distance from its 52-week high of $187.35 to its low of $127.59, indicating significant technical damage and positioning it as a potential value opportunity, though the persistent selling pressure suggests it remains a 'falling knife' for momentum traders. Recent momentum shows a stark divergence from the broader market, with BDX down 16.64% over the past three months while the SPY gained 10.28%, and a modest 1.25% gain over the past month still lags the SPY's 6.31% rally, highlighting severe relative weakness with a 1-year relative strength of -43.57. The stock's beta of 0.285 indicates it has been significantly less volatile than the market during this decline, which is atypical for a stock in a downtrend and may suggest a lack of speculative interest or capitulation selling. Key technical levels are clear, with immediate resistance at the recent breakdown area near the 52-week high of $187.35 and primary support at the 52-week low of $127.59; a breakdown below this support would signal a continuation of the bearish trend, while a recovery above the $170-$180 zone would be necessary to suggest a meaningful trend reversal.
Beta
0.28
0.28x market volatility
Max Drawdown
-32.2%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-14.7%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | +5.4% |
| 3m | -15.8% | +10.9% |
| 6m | -25.5% | +11.0% |
| 1y | -14.7% | +28.1% |
| ytd | -25.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
Revenue growth has been modest but positive, with the most recent quarterly revenue of $5.252 billion representing a 1.63% year-over-year increase. However, the trend shows volatility, as revenue declined sequentially from the prior quarter's $5.89 billion, and the two reported segments—Medical at $2.4 billion and Life Sciences at $2.5 billion—suggest a balanced but not accelerating growth profile. The company remains profitable, reporting net income of $382 million for the quarter, translating to a net margin of 7.68%. Gross margin for the quarter was a healthy 44.63%, though it has fluctuated between 42.8% and 47.5% over recent quarters, indicating some pressure or mix variability, while operating margin came in at 11.30%. Profitability metrics are solid but not exceptional, with Return on Equity (ROE) at 6.61% and Return on Assets (ROA) at 4.38%, reflecting the capital-intensive nature of the business. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.755, and the company generates substantial cash flow, with trailing twelve-month free cash flow of $2.631 billion. This strong FCF, coupled with a current ratio of 1.11, provides ample liquidity to fund operations, dividends (payout ratio of 71.3%), and share repurchases without reliance on excessive external financing, underpinning the company's financial resilience.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.44%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given the positive net income of $382 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 25.13x, while the forward PE is significantly lower at 10.97x, indicating the market expects a significant rebound in earnings over the next twelve months. Compared to sector averages, BDX's trailing PE of 25.13x trades at a premium to the broader market but is in line with many stable healthcare giants; however, the forward PE discount suggests the current price may not fully reflect anticipated profit growth if estimates are met. Historically, the stock's own valuation provides critical context: its current trailing PE of 25.13x is below the higher end of its historical range seen in recent quarters (e.g., 33.50x in Q1 2025 and 38.89x in Q1 2024) but above the lows near 13.35x from Q3 2025. This positioning in the mid-to-lower part of its historical band suggests the market has priced out previous optimism but may not be pricing in a catastrophic downturn, leaving room for multiple expansion if execution improves.
PE
25.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~107x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BDX faces margin pressure, with gross margin fluctuating between 42.8% and 47.5% over recent quarters and a Q1 net margin of just 7.68%. Revenue growth is tepid at 1.63% YoY, and the company depends on achieving its forward EPS estimate of $16.51 to justify its low forward P/E. An elevated dividend payout ratio of 71.3%, while covered by strong FCF, limits capital allocation flexibility if earnings falter. The balance sheet is conservative (D/E 0.76), mitigating near-term solvency risk.
Market & Competitive Risks: The primary risk is valuation compression despite the stock already trading at a discount. The trailing P/E of 25.13x, while below its historical highs, remains at a premium to many value stocks, and failure to meet growth expectations could lead to further multiple contraction. The stock's beta of 0.285 suggests it has been a defensive laggard, but its severe underperformance (-43.6% relative strength vs. SPY over 1 year) indicates it is being punished in the current market cycle, potentially due to sector rotation away from slower-growth medtech. Competitive pressures and pricing in its core medical supplies markets could further suppress top-line growth.
Worst-Case Scenario: The bear case unfolds if the company fails to deliver on its raised profit outlook, leading to earnings misses and downward revisions. This could trigger a loss of investor confidence, pushing the stock to retest its 52-week low of $127.59. Combined with a derating of the forward P/E multiple, this scenario implies a realistic downside of approximately -35% from the current price of $147.12. A breakdown below the $127.59 support level would signal a continuation of the bearish trend and potentially deeper losses, especially if the broader market enters a downturn.